₹57.93
Exchange Surveillance
- ASM Stage ILong Term Additional Surveillance Measure (LTASM) - Stage I
Price band ± 20%
Price
Trading Data
range barsReturns
absolute and vs benchmark indexAbout the Company
Krebs Biochemicals & Industries Limited (KBIL) is an India-based company. The Company operates in the pharma segment. The Companys products include lavastatin, simvastatin and simvastatin ammonium salt. The Company specializes in the fermentation technology. The Company has two manufacturing facilities: Unit-1 at Regadichelaka, Nellore district, and Unit-2 at Kothapalli Village, Kasimkota Mandal, Vishakapatnam district. Products manufactured from Unit I facility are ephedrine, pseudoephedrine and their salts, which are used for making formulations for respiratory ailments, such as cough and cold.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- HQ
- Vishakhapatnam, Andhra Pradesh
- Chairman
- R T Ravi
- CEO & MD
- Pabitrakumar Kalipada Bhattacharyya
- Registrar
- KFIN Technologies Pvt. Ltd.
- Exchange
- NSE
- ISIN
- INE268B01013
Institutional Demand
passive ownership through ETFsContext
where this company sitsFrequently Asked
▶What is the share price of Krebs Biochemicals and Industries Limited today?
Krebs Biochemicals and Industries Limited (KREBSBIO) is trading at ₹57.93. The price shown is the latest available from the exchange feed and updates through the trading session.
▶What is KREBSBIO’s P/E ratio versus the sector?
KREBSBIO trades at a P/E of —. Its industry median is shown alongside it in Key Stats, so you can see at a glance whether the stock is priced above or below the businesses it competes with. A lower P/E is not automatically cheaper — it can also reflect slower expected growth.
▶What is KREBSBIO’s dividend yield?
KREBSBIO has a dividend yield of 0.00%, based on dividends declared over the last twelve months against the current price. The full dividend history is on the News & Filings tab.
▶What is KREBSBIO’s 52-week high and low?
KREBSBIO has traded between ₹38.33 and ₹76.85 over the past year. The Trading Data block shows where the current price sits inside that band.
▶What is the market capitalisation of Krebs Biochemicals and Industries Limited?
Krebs Biochemicals and Industries Limited has a market capitalisation of ₹121 crore.
▶What is KREBSBIO’s return on equity?
KREBSBIO reports a return on equity of —. ROE measures profit generated per rupee of shareholder capital, and is most meaningful compared against others in Drug Manufacturers - Specialty & Generic.
▶Who are KREBSBIO’s competitors?
The Peers block on this page lists other Drug Manufacturers - Specialty & Generic companies with their price, P/E and market capitalisation. The Valuation tab compares multiples against the industry median in more depth.
▶What is KREBSBIO’s promoter holding?
Promoters hold 72.74% of KREBSBIO. The Ownership tab shows the full shareholding pattern — promoter, FII, DII and public — and how each has moved across recent quarters.
▶Which indices include KREBSBIO?
Index membership is listed in the Context block on this page, along with the weight KREBSBIO carries in each. That weight is what determines how much passive money tracks the stock.
▶Is Krebs Biochemicals and Industries Limited a good buy?
We do not publish buy or sell calls. What this page gives you instead is the evidence: our Value & Investment Index for where the price sits against its own history, the Fundamental Strength Index for the quality of the business, an investment checklist of criteria applied to every stock, and pros and cons generated from KREBSBIO’s own numbers. The judgement is yours.
KREBSBIO at a glance
Krebs Biochemicals and Industries Limited operates in the Drug Manufacturers - Specialty & Generic industry, part of the Healthcare sector. Krebs Biochemicals and Industries Limited (KREBSBIO) last traded at ₹57.93, giving it a market capitalisation of ₹121 crore. The 52-week range is ₹38.33 to ₹76.85, and the price is 51% of the way up that range. Promoters hold 72.74% of the company in the latest shareholding filing.
| Market cap | ₹121 crore |
|---|---|
| ROCE | -15.4% |